NRX Pharmaceuticals Sees Reduced Losses in 2024 NRX Pharmaceuticals reported a net loss reduction of $5 million in 2024, driven by lower R&D expenses. The company’s lead drugs, NRX-101 and NRX-100, are progressing toward FDA decisions in 2025. Strategic partnerships and clinic expansions are also in focus, despite challenges in financing and regulatory approvals.1